" Mannkind's CEO, Alfred Mann, speculates that in the ongoing trials Afrezza may demonstrate superior glycemic control; "I expect in this trial that compliant-AFREZZA patients will reach HbA1cs below the age American Diabetes Association's target of 7% and even the Endocrinology Society's goal of 6.5% and without increased risk of hypos. Indeed, my belief is that many patients are likely to reach A1Cs below 6%.". "

Is it safe to assume that MNKD has done their own small off the record trials on this over the years, just to satisfy their own curiosity?